control in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 4.98 [0.58; 42.68]
4.98 [0.58 ; 42.68 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 11,636 NA not evaluable symptomatic Covid-19detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.00 [2.35; 3.84]
3.00 [2.35 ; 3.84 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 17,177 NA not evaluable asymptomatic COVID casedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.04 [2.10; 4.41]
3.04 [2.10 ; 4.41 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 11,636 NA not evaluable infection (PCR positive symptomatic or not)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.26 [1.70; 3.00]
2.26 [1.70 ; 3.00 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 11,636 NA not evaluable severe COVID-19 occurrencedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.07; 61.14]
2.05 [0.07 ; 61.14 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 4.17 [2.43; 7.13]
4.17 [2.43 ; 7.13 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 18,494 NA not evaluable serious adverse eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.16 [0.85; 1.57]
1.16 [0.85 ; 1.57 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Bell's palsydetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.03 [0.21; 5.08]
1.03 [0.21 ; 5.08 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable immediate allergic reactiondetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.02; 15.28]
0.51 [0.02 ; 15.28 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable multiple sclerosisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.02; 15.28]
0.51 [0.02 ; 15.28 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable myelitisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.05; 5.65]
0.51 [0.05 ; 5.65 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Potential Immune Gastrointestinal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.08 [0.32; 29.58]
3.08 [0.32 ; 29.58 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Potential Immune Musculoskeletal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.03 [0.06; 16.40]
1.03 [0.06 ; 16.40 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Potential Immune Neuroinflammatory disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.82 [0.22; 3.06]
0.82 [0.22 ; 3.06 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Potential Immune Skin disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.37 [0.31; 6.11]
1.37 [0.31 ; 6.11 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Potential Immune Vasculitidesdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.07; 61.14]
2.05 [0.07 ; 61.14 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable Thromboembolic eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.62; 6.81]
2.05 [0.62 ; 6.81 ] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1 0% 23,745 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-24 06:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 649,650,589,651,968
- roots T: 290
